{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:59:02Z","timestamp":1793120342580,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR079428"],"award-info":[{"award-number":["R01AR079428"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jid.2024.10.597","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T02:40:01Z","timestamp":1732675201000},"page":"1471-1488.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Chemical, Biochemical, and Structural Similarities and Differences of Dermatological cAMP Phosphodiesterase-IV Inhibitors"],"prefix":"10.1016","volume":"145","author":[{"given":"Jimin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.10.597_bib1","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1021\/cr500642d","article-title":"Recent developments in the chemistry and biological applications of benzoxaboroles","volume":"115","author":"Adamczyk-Wo\u017aniak","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.jid.2024.10.597_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0968-0004(98)01293-6","article-title":"The HD domain defines a new superfamily of metal-dependent phosphohydrolases","volume":"23","author":"Aravind","year":"1998","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jid.2024.10.597_bib3","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/jm00037a021","article-title":"Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues","volume":"37","author":"Ashton","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.jid.2024.10.597_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/cells11020308","article-title":"Emerging role of cAMP\/AMPK signaling","volume":"11","author":"Aslam","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jid.2024.10.597_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmb.2004.07.047","article-title":"Electrostatic potential of nucleotide-free protein is sufficient for discrimination between adenine and guanine-specific binding sites","volume":"342","author":"Basu","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jid.2024.10.597_bib6","author":"Beeley","year":"1993","journal-title":"Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors"},{"key":"10.1016\/j.jid.2024.10.597_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/j.1460-2075.1991.tb07917.x","article-title":"Structural basis for the 3'-5' exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism","volume":"10","author":"Beese","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.jid.2024.10.597_bib8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jid.2024.10.597_bib9","first-page":"121","article-title":"PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on Roflumilast","volume":"2","author":"Boswell-Smith","year":"2007","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jid.2024.10.597_bib10","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3390\/ijms23042145","article-title":"Phosphodiesterases and compartmentation of cAMP and cGMP signaling in regulation of cardiac contractility in normal and failing hearts","volume":"23","author":"Calamera","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.10.597_bib11","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41467-018-04114-x","article-title":"The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation","volume":"9","author":"Capper","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2024.10.597_bib12","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"key":"10.1016\/j.jid.2024.10.597_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41419-024-06549-1","article-title":"Modulation of cAMP\/cGMP signaling as prevention of congenital heart defects in Pde2A deficient embryos: a matter of oxidative stress","volume":"15","author":"Cardarelli","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jid.2024.10.597_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tins.2005.06.005","article-title":"The many faces of CREB","volume":"28","author":"Carlezon","year":"2005","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jid.2024.10.597_bib15","doi-asserted-by":"crossref","first-page":"E1414","DOI":"10.1073\/pnas.1419906112","article-title":"Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4","volume":"112","author":"Cedervall","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.10.597_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/1744666X.2016.1134319","article-title":"A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast","volume":"12","author":"Chiricozzi","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jid.2024.10.597_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jid.2024.10.597_bib19","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1126\/science.7801124","article-title":"Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases","volume":"266","author":"Dyda","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jid.2024.10.597_bib20","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.jid.2024.10.597_bib21","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1073\/pnas.1709073114","article-title":"Different phosphodiesterases (PDEs) regulate distinct phosphoproteomes during cAMP signaling","volume":"114","author":"Epstein","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.10.597_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrd3276","article-title":"Roflumilast [published correction appears in Nat Rev Drug Discov 2024;23:563]","volume":"9","author":"Fabbri","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2024.10.597_bib23","series-title":"Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors","author":"Flockerzi","year":"1995"},{"key":"10.1016\/j.jid.2024.10.597_bib24","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1016\/j.febslet.2012.07.058","article-title":"Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center","volume":"586","author":"Freund","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jid.2024.10.597_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF00211020","article-title":"Mammalian adenylyl cyclase family members are randomly located on different chromosomes","volume":"94","author":"Gaudin","year":"1994","journal-title":"Hum Genet"},{"key":"10.1016\/j.jid.2024.10.597_bib26","doi-asserted-by":"crossref","first-page":"13040","DOI":"10.1073\/pnas.96.23.13040","article-title":"Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design","volume":"96","author":"Goldgur","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.10.597_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.pharmtox.41.1.145","article-title":"Regulation and role of adenylyl cyclase isoforms","volume":"41","author":"Hanoune","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jid.2024.10.597_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BST0390001","article-title":"AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer","volume":"39","author":"Hardie","year":"2011","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.jid.2024.10.597_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2024.10.597_bib30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/emboj\/18.4.893","article-title":"The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579","volume":"18","author":"Hoffmann","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.jid.2024.10.597_bib31","doi-asserted-by":"crossref","first-page":"13220","DOI":"10.1021\/bi034653e","article-title":"The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis","volume":"42","author":"Huai","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.jid.2024.10.597_bib32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tips.2019.04.001","article-title":"GPCRomics: an approach to discover GPCR drug targets","volume":"40","author":"Insel","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jid.2024.10.597_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314830","article-title":"ES-screen: a novel electrostatics-driven method for drug discovery virtual screening","volume":"23","author":"Issa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.10.597_bib34","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1021\/acs.jmedchem.5b01813","article-title":"PDEStrIAn: A phosphodiesterase structure and ligand interaction annotated database as a tool for structure-based drug design","volume":"59","author":"Jansen","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.jid.2024.10.597_bib35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.116.237743","article-title":"GS-5759, a bifunctional \u03b22-Adrenoceptor agonist and phosphodiesterase 4 inhibitor for chronic obstructive pulmonary disease with a unique mode of action: effects on gene expression in human airway epithelial cells","volume":"360","author":"Joshi","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jid.2024.10.597_bib36","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2024.10.597_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.3051385","article-title":"How do enzymes work?","volume":"242","author":"Kraut","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.jid.2024.10.597_bib38","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure-activity relationship insights and evolution perspectives","volume":"65","author":"La Monica","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.jid.2024.10.597_bib39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J Appl Crystallogr"},{"key":"10.1016\/j.jid.2024.10.597_bib40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2024.10.597_bib41","doi-asserted-by":"crossref","first-page":"13309","DOI":"10.1073\/pnas.0708850105","article-title":"Structural basis for the catalytic mechanism of human phosphodiesterase 9","volume":"105","author":"Liu","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.10.597_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.bjp.0704743","article-title":"Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved Region 1 (UCR1)","volume":"136","author":"MacKenzie","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2024.10.597_bib43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bjp.0704741","article-title":"Short-term regulation of PDE4 activity","volume":"136","author":"Manganiello","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2024.10.597_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1124\/mi.2.5.317","article-title":"GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides","volume":"2","author":"Martinez","year":"2002","journal-title":"Mol Interv"},{"key":"10.1016\/j.jid.2024.10.597_bib45","doi-asserted-by":"crossref","first-page":"13260","DOI":"10.1073\/pnas.192374899","article-title":"The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding","volume":"99","author":"Martinez","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.10.597_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7341493","article-title":"Paxlovid: mechanism of action, synthesis, and in silico study","volume":"2022","author":"Marzi","year":"2022","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jid.2024.10.597_bib47","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.csbj.2023.01.014","article-title":"Valproate-coenzyme A conjugate blocks opening of receptor binding domains in the spike trimer of SARS-CoV-2 through an allosteric mechanism","volume":"21","author":"Maschietto","year":"2023","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.jid.2024.10.597_bib48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm.4011","article-title":"Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling","volume":"22","author":"Myeku","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2024.10.597_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082360","article-title":"Pharmacophore modeling and virtual screening for the discovery of new type 4 cAMP phosphodiesterase (PDE4) inhibitors","volume":"8","author":"Niu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2024.10.597_bib50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/13543776.2018.1473379","article-title":"Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018)","volume":"28","author":"Nocentini","year":"2018","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jid.2024.10.597_bib51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.jid.2024.10.597_bib52","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1152\/physrev.00013.2021","article-title":"Physiological roles of mammalian transmembrane adenylyl cyclase isoforms","volume":"102","author":"Ostrom","year":"2022","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jid.2024.10.597_bib53","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1124\/pharmrev.120.000273","article-title":"The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitors","volume":"73","author":"Paes","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jid.2024.10.597_bib54","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/13543770903313753","article-title":"PDE4 inhibitors: a review of current developments (2005 - 2009)","volume":"19","author":"Pag\u00e8s","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jid.2024.10.597_bib55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/ijms22010186","article-title":"AMP-activated protein kinase: do we need activators or inhibitors to treat or prevent cancer?","volume":"22","author":"Russell","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.10.597_bib56","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives","volume":"24","author":"Sakkas","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jid.2024.10.597_bib57","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.jid.2024.10.597_bib82","author":"Schrodinger"},{"key":"10.1016\/j.jid.2024.10.597_bib58","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tips.2011.10.006","article-title":"Inhibitors of membranous adenylyl cyclases","volume":"33","author":"Seifert","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jid.2024.10.597_bib59","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.biochem.68.1.821","article-title":"CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals","volume":"68","author":"Shaywitz","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jid.2024.10.597_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/v13020205","article-title":"Integrase strand transfer inhibitors are effective anti-HIV drugs","volume":"13","author":"Smith","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jid.2024.10.597_bib61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jid.2024.10.597_bib62","doi-asserted-by":"crossref","first-page":"17395","DOI":"10.1074\/jbc.274.25.17395","article-title":"DNA polymerases: structural diversity and common mechanisms","volume":"274","author":"Steitz","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jid.2024.10.597_bib63","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1073\/pnas.90.14.6498","article-title":"A general two-metal-ion mechanism for catalytic RNA","volume":"90","author":"Steitz","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.10.597_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pa.36.040196.002333","article-title":"Complexity and diversity of mammalian adenylyl cyclases","volume":"36","author":"Sunahara","year":"1996","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jid.2024.10.597_bib65","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2024.10.597_bib66","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1073\/pnas.0700279104","article-title":"Structural insight into substrate specificity of phosphodiesterase 10","volume":"104","author":"Wang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.10.597_bib67","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jmb.2007.05.060","article-title":"The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10","volume":"371","author":"Wang","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jid.2024.10.597_bib68","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/j.jid.2023.03.1142","article-title":"1130 Clinically relevant differences in the chemical and structural mechanism of action of dermatological phosphodiesterase-4 inhibitors","volume":"143","author":"Wang","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.10.597_bib69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/acs.biochem.1c00755","article-title":"Insights into binding of single-stranded viral RNA template to the replication-transcription complex of SARS-CoV-2 for the priming reaction from Molecular Dynamics simulations","volume":"61","author":"Wang","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.jid.2024.10.597_bib70","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/acs.biochem.2c00341","article-title":"Structural insights into binding of remdesivir triphosphate within the replication-transcription complex of SARS-CoV-2","volume":"61","author":"Wang","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.jid.2024.10.597_bib71","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1021\/acs.biochem.2c00127","article-title":"Structural basis for reduced dynamics of three engineered HNH endonuclease Lys-to-Ala mutants for the clustered regularly interspaced short palindromic repeat (CRISPR)-associated 9 (CRISPR\/Cas9) enzyme","volume":"61","author":"Wang","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.jid.2024.10.597_bib72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1042\/BJ20131681","article-title":"The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s)","volume":"459","author":"Xie","year":"2014","journal-title":"Biochem J"},{"key":"10.1016\/j.jid.2024.10.597_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-00435-w","article-title":"G protein-coupled receptors: structure- and function-based drug discovery","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jid.2024.10.597_bib74","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCRESAHA.106.144501","article-title":"cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology","volume":"100","author":"Zaccolo","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.jid.2024.10.597_bib75","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/pharmrev.120.000086","article-title":"Subcellular organization of the cAMP signaling pathway","volume":"73","author":"Zaccolo","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jid.2024.10.597_bib76","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s11426-013-4981-y","article-title":"The synthesis of benzoxaboroles and their applications in medicinal chemistry","volume":"56","author":"Zhang","year":"2013","journal-title":"Sci China Chem"},{"key":"10.1016\/j.jid.2024.10.597_bib77","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.molcel.2004.07.005","article-title":"A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases","volume":"15","author":"Zhang","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.jid.2024.10.597_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113004","article-title":"Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment","volume":"211","author":"Zhang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jid.2024.10.597_bib79","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/MCB.01193-09","article-title":"Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D","volume":"30","author":"Zhu","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jid.2024.10.597_bib80","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","author":"Zuo","year":"2019","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24028859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24028859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:28:32Z","timestamp":1774258112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24028859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0022202X24028859"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.10.597","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical, Biochemical, and Structural Similarities and Differences of Dermatological cAMP Phosphodiesterase-IV Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.10.597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}